Viewing Study NCT04502433

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:08 AM
Ignite Modification Date: 2026-02-22 @ 2:37 AM
Study NCT ID: NCT04502433
Status: TERMINATED
Last Update Posted: 2023-06-23
First Post: 2020-08-03
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
Sponsor: Chiesi Farmaceutici S.p.A.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Respiratory Distress Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None acute respiratory distress syndrome View
None ARDS View
None Adults View
None Surfactant View
None Poractant alfa (porcine surfactant, Curosurf®), View
None Curosurf® View
None Coronavirus disease (COVID-19) View
None Coronavirus 2019 Disease View